Infections Due to Carbapenem-Resistant Bacteria in Patients With Hematologic Malignancies

In developed countries, hematological malignancies (HM) account for 8 to 10% of cancers diagnosed annually and one-third of patients with HM (HMP) are expected to die from their disease. The former wide spectrum “magic bullet,” imipenem, has been ousted by the emergence of carbapenem resistant (CR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lalaoui, Rym, Javelle, Emilie, Bakour, Sofiane, Ubeda, Carles, Rolain, Jean-Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379235/
https://www.ncbi.nlm.nih.gov/pubmed/32765433
http://dx.doi.org/10.3389/fmicb.2020.01422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379235/
https://www.ncbi.nlm.nih.gov/pubmed/32765433
http://dx.doi.org/10.3389/fmicb.2020.01422

Ejemplares similares